Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

This is a cross-sectional study in which the investigators will determine the impact of premature/early menopause on MSNA, BP and baroreflex sensitivity in younger (≤49 yr old) and older (≥50 yr old) women. Specifically, aim one will determine mechanisms driving autonomic dysregulation of BP in premature and early menopausal women and aim two will determine mechanisms driving autonomic dysregulation of BP in older menopausal women. The study design outlined below will permit testing of aim one and aim two.

Study Overview

• Status: Recruiting
• Conditions: Hypertension; Menopause; Blood Pressure; Menopause, Premature
• Intervention / Treatment: Diagnostic test: Microneurography to measure muscle sympathetic nerve activity (MSNA); Diagnostic test: Baroreflex sensitivity testing; Diagnostic test: Sympathoexcitatory Maneuvers; Diagnostic test: Blood tests

Detailed Description

Aim One: Determine mechanisms driving autonomic dysregulation of blood pressure (BP) in premature and early menopausal women. Because sympathetic activity and baroreflex function are important contributors for autonomic support of BP regulation, these two mechanisms will be assessed in premature and early menopausal women who are ≤49 yr old. To specifically identify the influence of menopause, these women will be compared to age-matched premenopausal women. The primary hypothesis is that there is greater resting sympathetic activity and blunted baroreflex function in premature and early menopausal women compared with age-matched premenopausal women. The secondary hypothesis is that BP and sympathetic reactivity will be greater in premature and early menopausal compared with age-matched premenopausal women when the sympathetic nervous system is challenged with a stressor.

Aim Two: Determine mechanisms driving autonomic dysregulation of BP in older menopausal women. Because older age contributes to risk of CVD, it is imperative to assess the long-term effects of premature and early menopause in older (≥50 yr) women. To determine the impact of the premature loss of sex hormones on cardiovascular physiology, women whom have lived without functioning ovaries for >10 yr will be compared to age-matched women who entered menopause at a typical age. The primary hypothesis is that resting sympathetic activity is greater and baroreflex function is attenuated in women who experience premature or early menopause compared with typically-aged menopausal women. The secondary hypothesis is that BP and sympathetic reactivity will be greater in premature and early compared with typically-aged menopausal women when the sympathetic nervous system is challenged with a stressor.

• Study Type: Observational
• Enrollment (Estimated): 160

Contacts and Locations

• Study Contact: Name: Manda Keller-Ross, PhD, DPT, PT; Phone Number: 612-625-3175; Email: kell0529@umn.edu

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Recruiting
      • University of Minnesota
      • Contact: Manda Keller-Ross, PhD, DPT, PT; Phone Number: 612-625-3175; Email: kell0529@umn.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Two scenarios of recruiting and enrolling premature/early menopausal females have been determined. 1) Enroll participants prior to starting MHT and/or 2) for patients already taking prescribed MHT, a standard protocol has been developed with Dr. Torkelson on guidelines for enrolling these participants. This includes a baseline estradiol (E2) blood draw, then in coordination with the participant and their physician, the participant will stop taking MHT. Estradiol will be tested every two weeks, up to 3 times (6 weeks). When estradiol is <30 pg/ml for two weeks, participants will be enrolled in the study and can commence MHT immediately upon completion of study visit.

Description

Inclusion Criteria:

• Aged 35-49 or 50-70 years of age who experienced premature (<40) or early (≤45) menopause
• Premenopausal 35-49 years of age
• Typical-age menopause (i.e., after 45 years of age), who are between 50-70 years old
• Menopause will be confirmed by subject report of amenorrhea for 12 months and serum FSH of >30 mIU/mL

Exclusion Criteria:

• Current nicotine/tobacco use within the past six months
• Are diabetic or asthmatic
• Have diagnosed significant carotid stenosis
• Have a history of significant autonomic dysfunction, heart disease, respiratory disease or a severe neurologic condition such as stroke or traumatic brain injury.
• Have existing metabolic or endocrine abnormities
• Take any heart/blood pressure medications that are determined to interfere with study outcomes
• IF the participant is premenopausal AND currently taking OC or other exogenous steroids that are determined to interfere with study outcomes
• Females who classify as having early or premature menopause AND are not willing to discontinue OC or MHT in order to complete the study
• Are pregnant or breastfeeding

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Aim 1: Postmenopausal Women; Participants in this group are postmenopausal women.	Diagnostic test: Microneurography to measure muscle sympathetic nerve activity (MSNA); Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves; Diagnostic test: Baroreflex sensitivity testing; Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.; Diagnostic test: Sympathoexcitatory Maneuvers; Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed; Diagnostic test: Blood tests; Serum FSH, estrogen, progesterone, and testosterone will be measured
Aim 1: Premenopausal Women; Participants in this group are premenopausal women.	Diagnostic test: Microneurography to measure muscle sympathetic nerve activity (MSNA); Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves; Diagnostic test: Baroreflex sensitivity testing; Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.; Diagnostic test: Sympathoexcitatory Maneuvers; Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed; Diagnostic test: Blood tests; Serum FSH, estrogen, progesterone, and testosterone will be measured
Aim 2: Premature/Early Menopause; Participants in this group women who experienced premature or early menopause.	Diagnostic test: Microneurography to measure muscle sympathetic nerve activity (MSNA); Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves; Diagnostic test: Baroreflex sensitivity testing; Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.; Diagnostic test: Sympathoexcitatory Maneuvers; Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed; Diagnostic test: Blood tests; Serum FSH, estrogen, progesterone, and testosterone will be measured
Aim 2: Typical-Age Menopause; Participants in this group are women who experienced menopause at a typical age.	Diagnostic test: Microneurography to measure muscle sympathetic nerve activity (MSNA); Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves; Diagnostic test: Baroreflex sensitivity testing; Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.; Diagnostic test: Sympathoexcitatory Maneuvers; Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed; Diagnostic test: Blood tests; Serum FSH, estrogen, progesterone, and testosterone will be measured

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle Sympathetic Nerve Activity (MSNA) (bursts per minute)	Muscle sympathetic nerve activity (MSNA) is a measurement of sympathetic activity. This is measured by two small needles are inserted behind or on the side of the knee, one needle is an acupuncture needle and one needle is a small recording microelectrode (same size as the acupuncture needle). Outcome will be reported in units of bursts per minute.	3 hours
Muscle Sympathetic Nerve Activity (MSNA) (bursts/100 heart beats)	Muscle sympathetic nerve activity (MSNA) is a measurement of sympathetic activity. This is measured by two small needles are inserted behind or on the side of the knee, one needle is an acupuncture needle and one needle is a small recording microelectrode (same size as the acupuncture needle). Outcome will be reported in units of bursts per 100 heart beats.	3 hours
Cardiac baroreflex sensitivity	Baroreflex sensitivity will be derived from electrocardiogram measurements and blood pressure measurements during the baseline rest period and by performing a modified valsalva maneuver which involves exhaling against 30-40 mmHg of pressure over 15 seconds after a normal inhalation. Outcome will be reported in units as ms/mmHg.	3 hours
Sympathetic baroreflex sensitivity	Baroreflex sensitivity will be derived from electrocardiogram measurements and blood pressure measurements during the baseline rest period and by performing a modified valsalva maneuver which involves exhaling against 30-40 mmHg of pressure over 15 seconds after a normal inhalation. Outcome will be reported in units of MSNA bursts/mmHg.	3 hours
Systolic Blood Pressure (mmHg)	Blood pressure is measured using a non-invasive blood pressure cuff secured to the middle or ring finger and reported in units of mmHg.	3 hours
Diastolic Blood Pressure (mmHg)	Blood pressure is measured using a non-invasive blood pressure cuff secured to the middle or ring finger and reported in units of mmHg.	3 hours
Mean Arterial Blood Pressure (mmHg)	Blood pressure is measured using a non-invasive blood pressure cuff secured to the middle or ring finger and reported in units of mmHg.	3 hours
Heart Rate (beats/min)	Heart rate will be measured with a three-lead electrocardiogram (ECG) and reported in units of beats/min.	3 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory Rate (breaths/min)	Respiratory rate will be measured with a belt placed around the stomach and reported in units of breaths-per-minute.	3 hours
Heart Rate Variability (frequency)	Heart rate variability will be measured using electrocardiogram and reported in units of Hertz.	3 hours
Heart Rate Variability (time)	Heart rate variability will be measured using electrocardiogram and reported in units of milliseconds.	3 hours
Borg Rating of Perceived Exertion	Participants will be asked to rate their perceived exertion using the Borg Rating of Perceived Exertion scale. Scores range from 6-20 with higher scores indicating greater exertion.	3 hours
Numerical Pain Scale Rating	Participants will be asked to rate pain on a scale from 0 to 10. Higher scores indicate greater pain.	3 hours
Blood Levels: Estrogens-E1	Serum concentration of estrogen-E1 will be reported in units of ng/ml.	75 minutes
Blood Levels: Estrogen-E2	Serum concentration of estrogen-E2 will be reported in units of ng/ml.	75 minutes
Blood Levels: Progesterone	Serum concentration of progesterone will be reported in units of ng/ml.	75 minutes
Blood Levels: Testosterone	Serum concentration of testosterone will be reported in units of ng/ml.	75 minutes
Blood Levels: Follicle-Stimulating Hormone (FSH)	Serum concentration of FSH will be reported in units of IU/L.	75 minutes
Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO)	This test involves holding a hand grip device at 30% of the participant's maximum hand grip strength until they fatigue. At the end of this test a blood pressure cuff is inflated for two minutes. The outcome measurements are the total change in systolic, diastolic and mean blood pressure from rest as well as how much blood pressure changes every 15 seconds. The measurement units are the change in blood pressure in mmHg.	3 hours
Cold Pressor Test	The cold pressor test is done by placing the participant's hand in a bucket of ice-cold water for 2 minutes. The outcome measurements are the total change in systolic, diastolic and mean blood pressure from rest as well as how much blood pressure changes every 15 seconds. The measurement units are the change in blood pressure in mmHg.	3 hours

Collaborators and Investigators

• Sponsor: University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2019
• Primary Completion (Estimated): April 30, 2025
• Study Completion (Estimated): April 30, 2025

Study Registration Dates

• First Submitted: October 28, 2019
• First Submitted That Met QC Criteria: June 17, 2020
• First Posted (Actual): June 19, 2020

Study Record Updates

• Last Update Posted (Estimated): April 15, 2024
• Last Update Submitted That Met QC Criteria: April 12, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Pregnancy Complications; Obstetric Labor Complications; Obstetric Labor, Premature; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Premature Birth; Primary Ovarian Insufficiency; Menopause, Premature
• Other Study ID Numbers: PT-2018-27097

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No